Expression of the Neu Protooncogene in the Mammary Epithelium of Transgenic Mice Induces Metastatic Disease

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1992 Nov 15

PMID 1359541

Citations 521

Authors

C T Guy

M A Webster

M Schaller

T J Parsons

R D Cardiff

W J Muller

Affiliations

Soon will be listed here.

Abstract

Overexpression and amplification of the neu (c-erbB2, ERBB2) protooncogene have been implicated in the development of aggressive human breast cancer. To directly assess the effect of mammary gland-specific expression of the neu protooncogene, transgenic mice carrying unactivated neu under the transcriptional control of the mouse mammary tumor virus promoter/enhancer were established. By contrast to the rapid tumor progression observed in several transgenic strains carrying the activated neu transgene, expression of unactivated neu in the mammary epithelium resulted in the development of focal mammary tumors after long latency. The majority of the mammary tumors analyzed expressed elevated levels of neu-encoded mRNA and protein. Overexpression of neu in the mammary tumors was also associated with elevated neu intrinsic tyrosine kinase activity and the de novo tyrosine phosphorylation of several cellular proteins. Interestingly, many of the tumor-bearing transgenic mice developed secondary metastatic tumors in the lung. These observations suggest that overexpression of the unactivated neu protein can induce metastatic disease after long latency.

Citing Articles

Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.

Gabriel E, Necela B, Bahr D, Vivekanandhan S, Shreeder B, Bagaria S Sci Rep. 2024; 14(1):24545.

PMID: 39427012 PMC: 11490618. DOI: 10.1038/s41598-024-76209-z.

Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model.

To B, Broeker C, Jhan J, Garcia-Lerena J, Vusich J, Rempel R Oncogene. 2024; 43(46):3402-3415.

PMID: 39341991 PMC: 11554565. DOI: 10.1038/s41388-024-03172-4.

Claudin 7 suppresses invasion and metastasis through repression of a smooth muscle actin program.

West J, Golloshi R, Cho C, Wang Y, Stevenson P, Stein-OBrien G J Cell Biol. 2024; 223(12).

PMID: 39320351 PMC: 11450322. DOI: 10.1083/jcb.202311002.

Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.

Treekitkarnmongkol W, Shah V, Kai K, Katayama H, Wong J, Ladha F Br J Cancer. 2024; 131(1):171-183.

PMID: 38760444 PMC: 11231151. DOI: 10.1038/s41416-024-02697-5.

A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer.

Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C Clin Exp Metastasis. 2024; 41(5):733-746.

PMID: 38717519 PMC: 11499368. DOI: 10.1007/s10585-024-10289-z.

References

Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

Drebin J, Link V, Stern D, Weinberg R, Greene M . Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 1985; 41(3):697-706. DOI: 10.1016/s0092-8674(85)80050-7. View

Southern E . Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975; 98(3):503-17. DOI: 10.1016/s0022-2836(75)80083-0. View

Paterson M, Dietrich K, Danyluk J, Paterson A, Lees A, Jamil N . Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991; 51(2):556-67. View

Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H . Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet. 1986; 1(8484):765-7. DOI: 10.1016/s0140-6736(86)91782-4. View

Bargmann C, Hung M, Weinberg R . Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 1986; 45(5):649-57. DOI: 10.1016/0092-8674(86)90779-8. View

Di Fiore P, PIERCE J, Kraus M, Segatto O, King C, Aaronson S . erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237(4811):178-82. DOI: 10.1126/science.2885917. View

Hudziak R, Schlessinger J, Ullrich A . Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987; 84(20):7159-63. PMC: 299249. DOI: 10.1073/pnas.84.20.7159. View

Muller W, Sinn E, Pattengale P, Wallace R, Leder P . Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988; 54(1):105-15. DOI: 10.1016/0092-8674(88)90184-5. View

10.

Bargmann C, Weinberg R . Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A. 1988; 85(15):5394-8. PMC: 281763. DOI: 10.1073/pnas.85.15.5394. View

11.

Bargmann C, Weinberg R . Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J. 1988; 7(7):2043-52. PMC: 454481. DOI: 10.1002/j.1460-2075.1988.tb03044.x. View

12.

King C, Kraus M, Aaronson S . Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985; 229(4717):974-6. DOI: 10.1126/science.2992089. View

13.

Semba K, Kamata N, Toyoshima K, Yamamoto T . A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A. 1985; 82(19):6497-501. PMC: 390744. DOI: 10.1073/pnas.82.19.6497. View

14.

Coussens L, Yang-Feng T, Liao Y, Chen E, Gray A, McGrath J . Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985; 230(4730):1132-9. DOI: 10.1126/science.2999974. View

15.

Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987; 49(4):465-75. DOI: 10.1016/0092-8674(87)90449-1. View

16.

Kraus M, Popescu N, Amsbaugh S, King C . Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987; 6(3):605-10. PMC: 553440. DOI: 10.1002/j.1460-2075.1987.tb04797.x. View

17.

van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R . Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987; 7(5):2019-23. PMC: 365313. DOI: 10.1128/mcb.7.5.2019-2023.1987. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Bargmann C, Hung M, Weinberg R . The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986; 319(6050):226-30. DOI: 10.1038/319226a0. View

20.

Melton D, Krieg P, Rebagliati M, Maniatis T, Zinn K, Green M . Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 1984; 12(18):7035-56. PMC: 320141. DOI: 10.1093/nar/12.18.7035. View